Higher Tisagenlecleucel Doses May Improve Outcomes in Youth With B-ALL
Overall, event-free, relapse-free survival improved in patients receiving higher doses of tisagenlecleucel, with no increased toxicity
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.